Research programme: antiviral immunostimulants - Kineta
Alternative Names: CB 183872; IB 657; rOAS-1Latest Information Update: 28 Aug 2018
Price :
$50 *
At a glance
- Originator Illumigen Biosciences
- Developer Kineta; KPI Therapeutics
- Class Antivirals; Enzymes; Ligases; Proteins
- Mechanism of Action Immunostimulants; Ribonuclease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Viral-infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co